Funding processes for new vaccines: The need for greater understanding of the economic issues

Journal of Public Health

Volumn 16, Issue 4, 2008, Pages 261-265

  Drummond, Michael ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness; Health policy; Reimbursement

Indexed keywords

HEPATITIS A VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFECT; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HEPATITIS A; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; MENINGOCOCCOSIS; MONEY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION; VERRUCA VULGARIS; VIRUS INFECTION;

EID: 48149105468     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-008-0199-4     Document Type: Review

References (18)

1. S Aballéa J Chancellor M Martin P Wutzler F Carrat R Gasparini J Toniolo-Neto M Drummond M Weinstein 2007 The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model Value in Health 10 98 116
2. M Brisson N Van de Velde P De Wals MC Boily 2007 The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canad Vaccine 25 5399 5408
3. Cohen DR, Henderson JB (1988) Health prevention and economics. Oxford University Press, Oxford
4. MG Deneke MR Arguedas 2003 Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs Expert Rev Vaccines 2 661 672
5. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of healthcare programmes. Oxford University Press, Oxford
6. MF Drummond C Chevat M Lothren 2007 Do we fully understand the economic value of vaccines Vaccine 25 5945 5957
7. J Ehreth 2003 The value of vaccination: a global perspective Vaccine 21 4105 4117
8. EH Elbasha EJ Dasbach RP Insinga 2007 Model for assessing human papillomavirus vaccination strategies Emerg Infect Dis 13 28 41
9. George B, Harris A, Mitchell A (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19 (11):1103-9
10. A Laupacis D Feeny AS Detsky PX Tugwell 1992 How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 4 473 481 Feb 15
11. KL Nichol 2003 The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines Vaccine 21 1769 75
12. Pellissier JM, Brisson M, Levin MJ (2007) Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine doi:10.1016/j.vaccine.2007. 09.066
13. MJ Postma P Jansema ML van Genugten ML Heijnen JC Jager LT de Jong-van den Berg 2002 Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence Drugs 62 1013 24
14. MJ Postma ML Heijnen P Beutels JC Jager 2003 Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for the Netherlands Expert Rev Vaccines 2 477 82
15. MD Rawlins AJ Culyer 2004 National Institute for Clinical Excellence and itsvalue judgments BMJ 329 224 227
16. P Rosenthal 2003 Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults Hepatology 37 44 51
17. DW Scheifele 2000 New vaccines and the rising cost of caring Paediatr ChildHealth 5 371 372
18. R Welte CL Trotter WJ Edmunds MJ Postma P Beutels 2005 The role of economic evaluation in vaccine decision-making: focus on meningococcal group C conjugate vaccine Pharmacoeconomics 23 855 74